Codexis lands $60M Trinity Capital term loan to refinance debt
What's the deal? Codexis, a Redwood City-based maker of enzymatic solutions for therapeutics manufacturing, has entered a $60 million senior secured term loan with Trinity CapitalDealroom has a profile for this one. Try Dealroom →. The company drew $42.5 million from the first tranche to retire debt held by Innovatus Life Sciences Lending Fund IDealroom has a profile for this one. Try Dealroom →.
Why now? The Innovatus loan would have begun amortizing in March 2027. The Trinity facility pushes that timetable out: 48 months of interest-only payments, with amortization starting in November 2030.
The deal is primarily a refinancing rather than new cash. Post-closing, Codexis reported $42.5 million in total outstanding debt.
What's the endgame? Codexis is trying to turn its ECO Synthesis platform — an aqueous enzymatic process for making oligonucleotides — into a commercial manufacturing business targeting demand for RNAi therapeutics. Recent milestones include a 50-gram siRNA supply agreement for preclinical work and new 100-gram-scale data.
"The new facility provides us with flexibility in our capital structure to advance many of our growth initiatives in the siRNA therapeutic sector," said Georgia Erbez, Codexis chief financial officer and chief business officer.
Trinity, which lends across tech, equipment, healthcare, sponsor finance, and asset-based verticals, has deployed more than $6.2 billion across over 490 investments since 2008. "Providing growth capital to innovative companies operating in attractive, high-growth markets is a core focus of Trinity Capital's business strategy," said Rob Lake, its senior managing director for healthcare and life sciences.
What could go wrong? The financing extends runway but does not itself demonstrate customer adoption. Codexis still has to prove ECO Synthesis can scale to GMP manufacturing and win commercial siRNA business.
The signal: The deal shows a pre-commercial biotech using debt refinancing — not fresh equity — to buy time while it industrializes its core platform, with repayment pressure deferred to the point where its manufacturing bet should pay off.
Read more: pr.lakeoconeebreeze.net
Image credit: USDAgov
